Three NeuroOncology Clinical Trials Enrolling Patients

The Brain Tumor Treatment and Rehabilitation Center at JFK University Medical Center is enrolling qualifying patients in three brain tumor/neuro-oncology clinical trials. The Center is co-located with JFK Johnson Rehabilitation Institute. 

• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1 (Denovo Biopharma). This randomized trial is for patients with newly diagnosed glioblastoma. The patients receive standard of care as well as study medication. The trial compares the timing of the study medication to standard of care treatment.

• EF-32 TRIDENT: A Pivotal, Randomized, Open-Label Study of Optune (TTFields, 200kHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Novocure). This trial is for patients with newly diagnosed glioblastoma. This is a randomized trial of concomitant chemoradiotherapy with the Optune device (a novel therapy which sends low level treating fields to the tumor to prevent growth) compared to utilizing the Optune device along with maintenance chemotherapy alone.
• EF-25 METIS: A Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) (Novocure). This trial is for patients with brain lesions from non-small cell lung cancer. This trial is a randomized trial to receive focused radiation to the brain lesions with or without the Optune device (a novel therapy which sends low level treating fields to the lesions to prevent growth).

For more information about The Brain Tumor Treatment and Rehabilitation Center at JFK University Medical Center or how to enroll in the clinical trials, visit HMHBrain.com. To schedule an appointment, call 732-321-7010.